Objective: We examined whether women reporting nighttime pain would have more actigraphy-measured evidence for disturbed sleep and would report feeling less rested compared with women without nighttime pain.
P ain, including somatic symptoms such as arthralgias, bodily aches and pains, musculoskeletal pain, and joint pain, is commonly reported by women transitioning through menopause. 1 Individuals with nonmalignant pain conditions commonly report sleep disturbances (with prevalence as high as 50%-88%) in association with chronic pain. 2 In cross-sectional studies, self-reported insomnia is related to pain severity 2<11 ; in longitudinal population-based studies, pain severity is associated with the incidence and/or persistence of insomnia. 12, 13 Notably, the literature focuses on chronic pain, yet manifestations of acute and chronic pain differ. Moreover, not every complaint of acute pain progresses to persistent/chronic pain, and most sleep complaints resolve when the pain abates.
Wrist actigraphy, a noninvasive method for objectively monitoring sleep-wake patterns, 11, 14 can provide unique information regarding temporal interrelations between sleep and pain. Specifically, actigraphy can detect disturbed rest-activity patterns and night-to-night variability in sleep, 15 which may be associated with pain. Thus, actigraphy can be an ecologically valid procedure for assessing longitudinal within-participant sleep-wake patterns. 16, 17 Actigraphy-pain relationships have been studied mainly in individuals with specific conditions, particularly fibromyalgia syndrome (FMS). These studies have been relatively brief, generally 1 week or less, which may not be long enough to detect covariation in sleep and pain. Other studies have averaged actigraphy measures across several nights to examine sleep-pain relationships (eg, Wilson et al 11 and O'Brien et al 18 ). Kop et al 19 monitored activity levels and concurrent symptom reports five times daily during a 5-day period. Sleep fragmentation, total sleep time (TST), and sleep efficiency did not differ significantly between FMS and nonpain control groups, but mean nocturnal activity level was higher and sleep latency was longer in the FMS group. In a week-long daily process study that modeled day-to-day within-person changes in pain and sleep, Tang et al 20 found that presleep pain predicted subsequent poorer sleep efficiency based on self-report but not sleep efficiency based on actigraphy or subjective sleep quality. A polysomnogram (PSG) study of sleep-related muscle activity in FMS detected disturbances in some sleep continuity measures and increased muscle activity but no reductions in sleep efficiency. 21 Women are more likely to experience pain symptoms during the menopausal transition. 22 Analyzing data from the Australian Longitudinal Study on Women's Health, Berecki-Gisolf et al 23 observed that, compared with premenopause, women transitioning to perimenopause and through 7 years postmenopause had higher odds of Boften[ experiencing painful/stiff joints. However, to our knowledge, no published study examining the association between pain and sleep in women during this life cycle phase has used repeated nightly objective measures of sleep and has controlled for effects of menopause stage and vasomotor symptoms (VMS), which also can be associated with disturbed sleep.
The current analysis focuses on a generally healthy, racially/ ethnically diverse cohort of midlife women participating in a multisite study of sleep during the menopausal transition. Participants wore a wrist actigraph for approximately 1 month in their home sleep environment to capture sleep patterns during one menstrual cycle. The aim of this analysis was to model night-to-night variation in actigraphic sleep measures and Bfeeling rested[ in relation to self-reported pain severity during the sleep period. We hypothesized that on nights on which pain was reported, compared with nights without pain, actigraphy would show more movement during sleep (higher movement and fragmentation index [MFI]) and more disturbed sleep (less TST and lower sleep efficiency) and women would report feeling less rested after waking up in the morning.
METHODS

Study design and participants
The Study of Women's Health Across the Nation (SWAN), initiated in 1996, is a multiethnic, community-based, cohort study of the menopausal transition. A total of 3,302 women were enrolled at seven sites in the Core SWAN: Boston, MA; Chicago, IL; Detroit area, MI; Los Angeles, CA; Oakland, CA; Newark, NJ; and Pittsburgh, PA. The study design and recruitment of the main cohort have been described in detail. 24 Each site recruited white women and a minority group sample. SWAN cohort eligibility criteria required women to be aged 42 to 52 years, be premenopausal or early perimenopausal, have an intact uterus and at least one ovary, have at least one menstrual period in the previous 3 months, not be using any sex steroid hormone in the previous 3 months, and not be pregnant.
The SWAN Sleep Study was a cross-sectional study of sleep patterns during a 1-month period that was conducted at four of the seven study sites (Chicago, Detroit area, Oakland, and Pittsburgh) from 2003 to 2005 and included 370 women aged 48 to 59 years. This subcohort included 328 premenopausal and perimenopausal and 42 postmenopausal white (all sites), African-American (Chicago, Detroit area, and Pittsburgh), and Chinese (Oakland) women; two women did not have a sleep study. Each site's institutional review board approved both the Core SWAN and the SWAN Sleep Study protocols, and all women gave their written informed consent to participate. Women were paid for participating in the study.
Eligibility for the SWAN Sleep Study was determined before and during participants' annual Core SWAN assessment. Efforts were focused on recruiting women who were premenopausal and perimenopausal as defined by the Core SWAN, but eligibility criteria were relaxed during the final year of the study to allow inclusion of postmenopausal women. Surgically postmenopausal women (G1%) and women using hormone therapy but not yet postmenopausal at the annual Core SWAN examination (approximately 23% of the cohort) were excluded (women who began hormone therapy after recruitment into the SWAN Sleep Study were included). Exclusion criteria also included factors known to affect sleep, including active cancer chemotherapy or radiation; regular shift work/night shift employment; oral corticosteroid use; regular consumption of more than four alcoholic drinks daily; and noncompliance with Core SWAN procedures (eg, missed 950% of annual visits, refused annual visit blood draw).
All Core SWAN participants meeting the eligibility criteria at the four SWAN Sleep Study sites were approached for participation. Of these, 30% declined to participate in the SWAN Sleep Study, mostly because of protocol time burden. As previously reported, 25 SWAN Sleep Study participants did not differ markedly from Core SWAN participants in self-reported demographic characteristics, health status, depressive symptoms, or sleep quality on annual visit 05. SWAN Sleep Study participants reported hot flashes slightly less frequently during a 2-week period preceding SWAN Sleep Study participation than did study nonparticipants (P G 0.02), but the frequency of night sweats or cold sweats did not differ.
Procedures and measures
Data for SWAN Sleep Study participants included 5 to 7 years of hormonal, behavioral, social, and psychological measures collected during the fifth through seventh annual Core SWAN visits. Core SWAN data used in this report were obtained from the baseline visit and the closest visit preceding the SWAN Sleep Study.
The SWAN Sleep Study protocol was initiated within 7 days of the beginning of the follicular phase of the menstrual cycle in women who were still menstruating. Sleep data were collected for an entire menstrual cycle or 35 days, whichever was shorter, to capture the influence of hormone fluctuation and VMS changes, which vary across the menstrual cycle and may affect sleep architecture or sleep quality across the menstrual cycle. Women who had long intervals between cycles or were postmenopausal were scheduled at their convenience.
Measures of sleep described in this report included subjective sleep symptoms, daily sleep diaries, wrist actigraphy, PSG-assessed apnea-hypopnea index (AHI) scores, and periodic leg movement with arousal index (PLMAI) scores. Menopausal characteristics were assessed by self-report. Diaries were completed twice daily, at bedtime and after awakening (variables described later). PSG sleep studies were conducted in participants' homes during the first 3 days of the protocol (Vitaport-3 [TEMEC VP3] ambulatory PSG monitor; TEMEC Instruments BV, Kerkrade, the Netherlands; see Hall et al 25 for details).
The wrist actigraph (Actiwatch-64 [AW-64]; Philips Respironics, MiniMitter, Bend, OR) was worn concurrently with the completion of sleep diaries to provide a behavioral assessment of participants' habitual sleep. Analyses were limited to actigraphy days 4 to 30 (27 d) because instrumentation for concurrent PSG recordings on the first three nights may have introduced additional movement during sleep and because data were sparse after 30 days. Analyzable actigraphy data were obtained from 314 women and were available for a mean (SD) of 23.1 (5.1) days and a median (interquartile range) of 26.0 (7.0) days for each woman (interquartile range is the difference between upper quartile and lower quartile). A total of 185 women (58.9%) had data for all 27 nights, and 292 women (92.9%) had data for 15 nights or more. Actigraphy data were collected in 1-minute sampling epochs, and sleep-wake variables were calculated using the Actiware version 5.04 software program time above threshold mode at medium sensitivity. Bedtimes and rise times recorded in participants' diaries were used to set the parameters for total time in bed in the actigraphy software.
Dependent variables
Dependent variables were derived from wrist actigraphy and morning sleep diary reports . Three actigraphy variables were defined and computed as follows: (1) MFI is a composite measure of movement and brief (G1 min) immobility intervals and is expressed as a percentage of the sleep period, with higher values indicating greater restlessness during sleep; (2) actual sleep time is the amount of time between sleep start and sleep end that is scored as sleep, a measure of TST; and (3) sleep efficiency is the percentage of time in bed that is scored as sleep, calculated by dividing the actual sleep time by the time in bed (Â100). Pittsburgh Sleep Diary (PghSD) 26 Yderived Bfeeling rested[ is a subjective report of how rested one feels upon waking up in the morning and is coded from 0 (not at all) to 4 (extremely).
Independent variables Pain measure
The primary independent variable was nighttime pain severity, which was added to the original PghSD and measured by waketime diary ratings. Participants were instructed to record every morning the level of pain severity (0, not at all; 4, extremely) experienced on the previous night. Two response categories (B3[ [quite] and B4[ [extremely]) were combined because together they accounted for only 4% of the responses.
Covariates
Covariate data were obtained from the PghSD and Core SWAN assessments, as indicated later.
Sociodemographics
Age was a continuous variable recorded at the time of the SWAN Sleep Study. Race/ethnicity was determined by selfidentification as African American, white, or Chinese. Site was recorded as Chicago, University of California Davis (Oakland), Michigan (Detroit area), or Pittsburgh. Because of heterogeneity within site and race/ethnicity, a variable with eight categories was created to represent each site and race/ethnicity category (ie, African American and Chicago, white and Chicago, etc). Education (a five-level categorical variable indicating the highest level attained) was obtained from Core SWAN baseline, and marital status (a three-level categorical variable defined as single, separated/divorced/widowed, or married) was obtained from the most recent Core SWAN visit preceding the SWAN Sleep Study assessment.
Menopause status and use of hormone therapy
Transition status was determined using bleeding criteria, 27 and participants were classified into one of four categories: (1) premenopausal (no change in menstrual bleeding regularity) or early perimenopausal (menses in the preceding 3 mo with an increase in bleeding irregularity); (2) late perimenopausal (menses in the previous 12 mo but not in the previous 3 mo); (3) postmenopausal (at least 12 mo of amenorrhea); or (4) indeterminate. The latter group consisted of women who were not yet postmenopausal but reporting any hormone therapy use after their last Core SWAN assessment visit preceding SWAN Sleep Study participation. Women were categorized into Bundetermined[ menopause status because hormone therapy use affects bleeding patterns.
Vasomotor and menstrual symptoms
Nocturnal VMS (nVMS) were assessed using the PghSD. 26 Each morning, participants recorded the frequency and severity of three symptoms (cold sweats, hot flashes, and night sweats) that they may have experienced during the previous night. nVMS were coded as a binary variable: yes (B1[ if at least one of the three symptoms) or no (B0[ if none of the symptoms). If data were missing for only one of the three symptoms, the nVMS score was based on the two available symptoms; but if data were missing for two symptoms, we scored that night's nVMS as Bmissing,[ unless the one available symptom recorded was present. Nocturnal menstrual symptoms/cramps also were coded as present or absent.
Bodily pain (36-item Short-Form Health Survey) during Core SWAN visits
To index each participant's pain level across the years before the SWAN Sleep Study, we computed the median 36-item Short-Form Health Survey (SF-36) Bodily Pain subscale (BP) score for each woman based on all of her bodily pain percentile scores. The SF-36 is a widely used self-report measure of health-related quality of life, 28 and the BP subscale consists of two questions that assess the level of pain severity and the extent to which pain has interfered with function. It was administered in the Core SWAN at baseline and on follow-up visits 1 to 4, 6, and 8. The original coding algorithm was used, in which raw scores are transformed into a percentile score (range, 0-100), with higher scores indicating less pain. The subscale has good reliability and construct validity, 29, 30 and norms have been published. 31, 32 Body mass index Body mass index (BMI) was a continuous measure (weight [kg]/height [m 2 ]) obtained on the nearest Core SWAN visit preceding the SWAN Sleep Study.
Antidepressant, sleep, and pain medications
Daily medication use (prescription and over-the-counter), recorded at SWAN Sleep Study protocol inception and in the PghSD, was coded according to the World Health Organization Anatomical Therapeutic Chemical classification. 33 For these analyses, concurrent use of pain, sleep, or antidepressant medications from the following drug classes was coded: anti-inflammatory/antirheumatic products, nonsteroids (M01A), muscle relaxants, centrally acting agents (M03B), opioids (N02A), other analgesics and antipyretics (N02B), antimigraine preparations (N02C), antiepileptics (N03A), anxiolytics (N05B), hypnotics and sedatives (N05C), antidepressants (N06A), psycholeptics and psychoanaleptics in combination (N06C), and antihistamines for systemic use (R06A).
PSG sleep disturbances
AHI and PLMAI were obtained from the PSG performed on the first actigraphy night, and both indices were scored according to standard criteria. 34, 35 
Actigraphy recordings
Actigraphy study night and whether each individual actigraphy day was a weekday or weekend were included as time-varying covariates.
Data analysis
A total of 331 women completed actigraphy data collection. Because concurrent PSG instrumentation during the first three nights could interfere with a Busual night's sleep,[ we excluded these nights from the analysis, leaving 327 women eligible for this analysis (4 women had data on only these 3 d).
Although there was no reported equipment failure, 13 women were excluded from this analysis because most (950%) of their observed values for fragmentation index were zero. Because this is not a valid value for a participant wearing a functioning actigraph, it was presumed that they were not wearing the device. Thus, 314 women contributed longitudinal data for the analysis, for a total of 7,472 nights (~23.8 nights per woman).
Univariate statistics, including means (SDs) and medians (interquartile ranges), were computed for continuous variables, and frequencies were determined for categorical variables. Variables with highly skewed distributions were transformed or categorized. To reduce skewness, we conducted square root transformation for the MFI. Sleep efficiency was treated as a dummy variable (Q85% or G85%).
Linear mixed-effects modeling (SAS Proc Mixed) with random intercept and slope was used to evaluate the associations between self-reported nighttime pain severity scores and continuous variables (MFI and TST; data presented as A [SE]), whereas generalized linear mixed-effects modeling (SAS Proc GLIMMIX) with random intercept and slope was used to model the effects of self-reported nighttime pain on dichotomized Bfeeling rested[ (moderate/quite a bit/extremely vs not at all/a little) and dichotomized sleep efficiency (Q85% vs G85%); (data presented as odds ratio [95% CI]). We chose this sleep efficiency cut point because a value less than 85% is below the lower limit of the normative range for middle-aged women. 36 The mixed-effects modeling approach combined the crosssectional (between women) and longitudinal (within women) estimates of association while correcting those estimates for multiple and correlated measures within women. All models used the autoregressive AR(1) structure, except for the model with dichotomized sleep efficiency and dichotomized Bfeeling rested[ as outcome, which used the unstructured covariance matrix structure. The models were evaluated using Akaike information criterion and likelihood ratio statistics.
Three mixed-effects regression models were fitted for each actigraphy outcome. The first (Bunadjusted[) model analyzed the pain severity variable on sleep outcomes. In the second (Bforced covariates[) model, the following covariates were added: study site and race/ethnicity, participant age (at the beginning of the SWAN Sleep Study), menopause status, nVMS, and SF-36 BP score. In the third (Bfully adjusted[) model, BMI, AHI, PLMAI, weekend/weekday actigraphy night, medications, educational level, and marital status were added. Sleep study night for each participant was included in the fully adjusted model to capture night-to-night variations.
All analyses were conducted with SAS version 9.3 (SAS, Cary, NC). Two-tailed P G 0.05 was considered statistically significant. Table 1 shows the characteristics of the 314 participants included in this analysis, as well as comparisons between the group that reported pain on at least one night (n = 211; 67%) and the group that reported no pain on any night (n = 103; 33%). These two groups were similar in most characteristics, except for menopause status (higher percentages of premenopausal and perimenopausal in the no-pain group, P = 0.02), difficulty paying for basics (higher percentage reporting Bnot very[ in the no-pain group, P G 0.05), and BMI (greater in the pain group, P = 0.01). A larger percentage of women in the pain group reported taking pain medication (68% of the pain group vs 45% of the no-pain group, P G 0.0001). Those who reported taking pain medication had a mean (SD) use of 12.1 (10.0) days. A larger percentage of the no-pain group reported taking medication for sleep during the study (P = 0.04). The mean (SD) SF-36 BP percentile score was 72.2 (18.6) (n = 298), similar to published age-standardized and sex-standardized scale scores, 31, 32 but the median score was lower (ie, more pain) in the pain group (P G 0.0001). Women reported nVMS for a median (interquartile range) of 9 (15) nights, and the pain and no-pain groups did not differ significantly in the median number of nights with nVMS.
RESULTS
Sample characteristics
Covariates
Aside from the site-race variable, the only covariate that was significantly associated with at least three of the sleep-related outcome measures in the fully adjusted analyses was nVMS. In fully adjusted models, nights on which VMS were reported were associated with higher odds of motor restlessness, lower odds of having a sleep efficiency of 85% or higher, and lower odds of feeling moderately, quite, or extremely rested in the morning. There were other statistically significant associations (P G 0.05) between covariates and actigraphy or PghSD outcomes. Compared with married women, single women had a significantly higher MFI and lower odds of having a sleep efficiency of 85% or higher. PLMAI and antidepressant medication use also were associated with a higher MFI, and sleep on weekends and use of sleeping medication were associated with a longer TST (17.5 and 17.6 min, respectively). Reporting less past bodily pain (SF-36 BP score) and weekend sleep both were associated with higher odds of feeling Bmoderately,[ Bquite,[ or Bextremely[ rested in the morning. BAny pain[ was defined as reporting nighttime pain/discomfort in the sleep diary on at least one actigraph-recorded night during the whole study. BNo pain[ was defined as reporting no nighttime pain/discomfort in the sleep diary on any actigraph-recorded night during the whole study.
Pain severity and actigraphy-assessed sleep measures
Associations between self-reported nighttime pain severity scores and continuous sleep variables (MFI and TST) are shown in Table 2 , and the effects of self-reported nighttime pain on dichotomized Bfeeling rested[ and dichotomized sleep efficiency are shown in Table 3 . As expected, the pain severity parameter estimates (A coefficients) for the MFI outcome were larger for each successively greater pain level, but neither the unadjusted model nor the adjusted models showed statistically significant associations. TST was significantly associated with nighttime pain, but in the direction opposite to that expected: women reporting nighttime pain averaged 5.2 to 12.1 minutes more sleep than women reporting no pain. In the fully adjusted model, pairwise comparisons with Bno pain[ showed that both Bslight[ pain (6.7 min, P G 0.05) and Bmoderate[ pain (12.1 min, P = 0.001) were associated with more sleep time.
Sleep efficiency, an estimate of the percentage of time in bed actually spent sleeping, was significantly associated with nighttime pain in the fully adjusted model (P = 0.02). For successively higher levels of nighttime pain, the odds ratios for sleep efficiency of 85% or higher were monotonically lower.
In the fully adjusted model, the pairwise comparison was significant between nights with Bquite/extremely[ severe pain versus none (odds ratio, 0.51; 95% CI, 0.31-0.82; P G 0.006), indicating that nights with extreme pain were associated with a 49% reduction in the odds of sleeping at least 85% of the time spent in bed compared with nights with no pain.
In unadjusted and adjusted models, the effects of pain severity on Bfeeling rested[ were reflected in the sleep efficiency data, and the overall P values were highly significantly related to Bfeeling rested[ (P G 0.0001). On average, the no-pain group felt at least moderately well rested on 2.3 nights more than the pain group (A [SE], 19.1 [0.7] vs 16.8 [0.5]; P G 0.006). In all models, higher levels of nighttime pain severity were related to significantly lower odds (29%-72% lower in fully adjusted models) of feeling well-rested upon awakening in the morning.
DISCUSSION
Experiencing pain during sleep may be a relatively common experience for middle-aged women (as about two thirds of our sample reported at least slight pain or discomfort on at least one actigraph-recorded night) and was reported on 24% of 7,472 nights. To our knowledge, this is the first study to examine associations between night-to-night pain self-reports and actigraphy-assessed sleep disturbances in community-dwelling middle-aged women. Linear mixed model analysis is a useful approach to examining variability in temporal patterns of sleep measures across multiple nights within individuals and for comparing differences between individuals. 37 After adjustment for other variables that could influence sleep in midlife women, pain severity was associated with two components of sleep: a lower percentage of time in bed spent asleep (lower sleep efficiency) and longer sleep duration (TST) in women reporting Bslight[ or Bmoderate[ pain. Subjectively, women who reported higher levels of pain severity felt less rested upon awakening in the morning.
Pain can produce repetitive arousals and can disrupt the continuity of sleep, resulting in sleep deprivation, which can heighten pain perception the next day. 14,38<40 However, we did not find differences in our actigraphy-assessed measure of restlessness (MFI) during sleep, nor did we find a significant TST effect in the severe pain group as we did in the Bslight[ and Bmoderate[ pain severity groups. This nonlinear relationship between pain severity and TST, as well as the unexpectedly and perhaps paradoxically significant association in the direction opposite to what we had hypothesized, raises a question on whether women with milder pain stay in bed longer trying to sleep despite pain, thereby accumulating more sleep time but at the expense of spending a disproportionately greater time in bed not sleeping and, hence, a lower sleep efficiency. Another consideration is that actigraphy can overestimate sleep when someone is lying in bed awake, so higher actigraphy TST on pain nights may also reflect longer time lying quietly awake. Therefore, despite 11 observed that pain severity was associated only with sleep diary measures and suggested that actigraphy could be insensitive to the magnitude of sleep disturbance in individuals with high-severity pain if they were immobile during periods of extended wakefulness. However, only two nights of actigraphy were recorded. Our middle-aged women were not selected for sleep or pain problems, as were the samples of O'Brien et al 18 and Wilson et al, 11 which included younger groups of men and women with chronic musculoskeletal pain.
Determining the causal role of various factors that can influence sleep and pain is challenging. 41 In our sample, we statistically controlled for a number of factors that may be associated with pain and sleep disturbance in midlife women, including sociodemographics, menopausal symptoms, polysomnographic measures of common sleep disturbances (sleep apnea and periodic leg movements in sleep), and medication use. Although we had no information on specific acute/chronic pain conditions, we controlled for history of bodily pain using participants' SF-36 BP scores obtained annually for up to 6 years before the SWAN Sleep Study. Women reporting nighttime pain tended to report more severe and impairing pain in previous years (Table 1 ). This indicator of pain chronicity also was significantly associated with feeling (less) rested in the morning.
A number of other factors also were associated with the sleep outcomes. As might be expected in women traversing the menopausal transition, nVMS were significantly associated with motor restlessness in bed (ie, MFI) and they were less likely to have good sleep efficiency or to feel at least moderately rested in the morning. The effect of nVMS on sleep-related restlessness was significant even after controlling for the effects of PLMAI, which also involves motor activity during sleep and was significantly associated with MFI.
Marital status also correlated with the actigraph measures of MFI and sleep efficiency. Consistent with another analysis from this sample, 42 single women had significantly more nighttime movement/restlessness and were less likely to sleep at least 85% of the night in bed than did married women. However, we hesitate to speculate on its implications because we do not know what proportion of single or married/cohabiting women slept alone in our cohort.
Nights that preceded a weekend were significantly associated with actigraphy-measured longer sleep duration (TST) and subjectively assessed Bfeeling rested,[ but not with sleep efficiency or movement/restlessness (MFI). Together, these observations seem to suggest that the subjective benefit of Bsleeping in[ on weekends may extend to lengthening the time in bed but not necessarily to how efficiently one sleeps. Among the medication groups examined, use of antidepressant medications was associated with more restlessness in bed, and sleep medication was associated with longer sleep duration. The latter finding is consistent with their advertised goal of treatment, and the former has been reported to be attributable to the pharmacologic effects of certain agents within this group of medications on processes regulating sleep and wakefulness, such as serotonin reuptake inhibitors. 43, 44 Limitations of our study are related to the lack of information on the chronicity, specific type, and location of pain, as well as the known limitations of actigraphy. 15, 17 Nevertheless, actigraphy is the most convenient and ecologically valid means to objectively measure habitual sleep. Because our sample was limited to middle-aged women, it remains unclear whether the results can be generalized to men or other age groups. Also, we acknowledge that, despite the statistically significant associations of pain and VMS with sleep outcomes, both accounted for little variance in these measures (R 2 for pain = 0.18%-1.57%; R 2 for VMS = 0.10%-0.20%). Nevertheless, in the case of pain, even small influences could have a meaningful impact on public health because an estimated 100 million persons in the United States are affected by chronic pain. 45 VMS (especially severe VMS) can affect sleep, and sleep problems increase across the menopausal transition. However, other factors, such as mood, may account for associations between VMS and sleep. 46<48 Finally, because of the lack of information about the onset or chronology of pain or sleep symptoms, we could not examine the bidirectionality hypothesis on sleep-pain relationships in this cross-sectional design. Our approach was to model night-to-night variation in actigraphic sleep measures as a function of self-reported nighttime pain during the course of one menstrual cycle. Experimental models have shown that sleep and pain interact in complex ways, suggesting that the relationship can be bidirectional, but perhaps not in a reciprocal relationship such as that which has been described. 20, 41 This study has significant and unique strengths. First, we studied a large community sample of women unselected for the presence of pain or sleep problems to enhance the generalizability of the results. Second, we analyzed actigraphy data collected for up to 27 consecutive nights, longer than any other study of sleep-pain relationships, and took interindividual and intraindividual variability into account. Third, our large sample and the large number of observations afforded by this longitudinal data analysis provided sufficient statistical power to control for the effects of a number of covariates known or suspected to be associated with sleep and/or pain.
CONCLUSIONS
Midlife women who report more severe pain levels demonstrate more actigraphy-assessed sleep disturbance and subjectively assessed less restful sleep. However, pain is just one of a host of factors disturbing sleep. Thus, complaints of sleep problems in women with pain require a thorough clinical assessment of other possible contributing factors, particularly if controlling pain does not improve sleep.
